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Abstract The aim of this studywas to assess whether the use of
accelerated MRI scans in place of non-accelerated scans influ-
enced brain volume and atrophy rate measures in controls and
subjects with mild cognitive impairment and Alzheimer’s dis-
ease.We used data from 861 subjects at baseline, 573 subjects at
6 months and 384 subjects at 12 months from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI). We calculated whole-
brain, ventricular and hippocampal atrophy rates using the k-
means boundary shift integral (BSI). Scan quality was visually
assessed and the proportion of good quality accelerated and non-
accelerated scans compared. We also compared MMSE scores,
vascular burden and age between subjects with poor quality
scans with those with good quality scans. Finally, we estimated
sample size requirements for a hypothetical clinical trial when
using atrophy rates from accelerated scans and non-accelerated
scans. No significant differences in whole-brain, ventricular and
hippocampal volumes and atrophy rates were found between
accelerated and non-accelerated scans. Twice as many non-
accelerated scan pairs suffered from at least some motion arte-
facts compared with accelerated scan pairs (p ≤ 0.001), which
may influence the BSI. Subjects whose accelerated scans had
significant motion had a higher mean vascular burden and age
(p ≤ 0.05) whilst subjects whose non-accelerated scans had sig-
nificant motion had poorer MMSE scores (p ≤ 0.05). No differ-
ence in estimated sample size requirements was found when
using accelerated vs. non-accelerated scans. Accelerated scans
reduce scan time and are better tolerated. Therefore it may be
advantageous to use accelerated over non-accelerated scans in
clinical trials that use ADNI-type protocols, especially in more
cognitively impaired subjects.
Keywords Accelerated acquisition . Alzheimer’s disease .
Boundary shift integral . Brain atrophy . Non-accelerated
acquisition . Image quality
Introduction
Volumetric magnetic resonance imaging (MRI) plays a key role
in diagnosis, research and clinical trials in dementia. Single
time-point structural MRI of the brain allows for the visualisa-
tion of atrophy patterns and quantification of brain volumes,
which can aid diagnosis in neurodegenerative diseases.
Volumes derived from a single MRI encapsulate prior atrophy
but also a large amount of inter-subject variation. Serial MRI
allows each individual to act as his or her own control meaning
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changes in volume can be visualised and measured. Such lon-
gitudinal measures have less variability and can be used to track
progression allowing objective assessment of the effects of po-
tentially disease-modifying therapies. This necessitates co-
registration of the image series and for quantification, the ap-
plication of techniques such as the boundary shift integral (BSI)
to pairs of images (Fox and Freeborough 1997; Leung et al.
2010). Atrophy rates, as measured using the BSI have been
shown to be sensitive biomarkers for Alzheimer’s disease
(AD) and have been used as outcome measures in a number
of clinical trials (Fox et al. 2005; Jack et al. 2008; Salloway
et al. 2014). However, the quality of each scan in the series is
important to provide robust and accurate results. Poor quality
scans can be caused by patient-related factors such as move-
ment during the scanning process.
A typical 3T 3D structural brain MRI with 1 mm resolution
takes approximately 9 min to acquire but some subjects have
difficulty remaining still for this time period, often resulting in
motion artefacts rendering them unusable for quantification.
Acquisition times can be reduced by employing parallel imag-
ing techniques (e.g. with scan times of approximately 5 min),
potentially reducing motion artefacts, scanning costs, as well
as increasing patient comfort and compliance. Reducing scan-
ning time may mean that a higher proportion of subjects re-
cruited to a study or clinical trial has useable MRI scans.
However, accelerated acquisitions alter scan characteristics
such as signal-to-noise ratio, noise distribution and tissue con-
trast. Before accelerated T1 scans can be used in place of non-
accelerated T1 scans in clinical trials, it is essential that we
understand how accelerated acquisitions may affect cross-
sectional volumes and longitudinal atrophy rate measures.
Previous studies have investigated the influence of using accel-
erated protocols in place of non-accelerated cross-sectionally on
freesurfer morphometry measures (Wonderlick et al. 2009) and
longitudinally on tensor based morphometry (TBM) based atro-
phy measures (Ching et al. 2015; Hua et al. 2016; Vemuri et al.
2015). Another study investigated the impact of changing from
non-accelerated baseline scans to an accelerated follow-up scans
on boundary shift integral (BSI) and deformation-based mor-
phometry measures of atrophy (Leung et al. 2015). To date,
however, there has been no study investigating the influence
of using accelerated scans in place of non-accelerated at both
baseline and follow-up, on the BSI, an important clinical trial
outcome measure. TBM based atrophy measures and the BSI
rely on different properties of MRI scans to quantify change
necessitating assessment of the impact of using accelerated
MRI scans on the BSI; the BSI tracks how much the surface
of the brain (or structure of interest) hasmoved between baseline
and follow-up by measuring changes in voxel intensities in a
region around the brain boundary whereas TBM based mea-
sures use non-linear registration to align baseline and follow-
up scans and volume change is estimated from the gradients of
the resulting deformation fields. In addition, despite poor quality
MRI scans routinely being excluded from studies (for reasons
such as head coil failure, geometric distortions or patient mo-
tion), the question of whether subject characteristics differ be-
tween those who have useable MRI scans with those who have
poor quality scans (due to patient motion) needs to be evaluated.
Therefore, the aims in this study were to: 1) compare whole
brain, ventricular and hippocampal volumes at baseline and
atrophy rates (measured using the BSI) over 6-month and 12-
month intervals in accelerated and non-accelerated scans, 2)
investigate whether there was a difference in the proportion
of good quality accelerated and non-accelerated scans, 3) as-
sess whether subject characteristics differed between subjects
whose scans were considered unusable due to motion com-
pared with those whose scans were of good quality and 4)
compare estimated sample size requirements for a hypothetical
clinical trial when using accelerated and non-accelerated scans.
Materials and Methods
Image Data and Acquisition
Data used in the preparation of this article were obtain-
ed from the Alzheimer ’s Disease Neuroimaging
Initiative (ADNI) database (adni.loni.usc.edu). The
ADNI was launched in 2003 as a public-private partner-
ship, led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test wheth-
er serial magnetic resonance imaging (MRI), positron
emission tomography (PET), other biological markers,
and clinical and neuropsychological assessment can be
combined to measure the progression of mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD).
For up-to-date information, see www.adni-info.org.
ADNI-GO and ADNI-2 included both accelerated and
non-accelerated acquisition protocols for each partici-
pant. At the time of downloading baseline MRI scans
were available for a total of 861 subjects, 6 month
scans for 572 subjects, and 12 month scans for 384
subjects. All subjects used in the preparation of this
article were scanned on 3T scanners and were new re-
cruits to ADNI-GO/2. Image pre-processing included
post-acquisi t ion correction of gradient warping
(Jovicich et al. 2006) and intensity non-uniformity cor-
rection using N3 (Sled et al. 1998). Scanners from three
different manufacturers (Philips, Siemens and General
Electric) were in use across the different sites. The three
different scanner manufacturers use different accelera-
tion protocols; details of the various MRI protocols are
listed on the ADNI website (http://adni.loni.usc.
edu/methods/documents/mri-protocols/). Non-accelerated
scans were always acquired prior to the accelerated
scans during the same scanning session. Subject
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demographics for all subjects with both accelerated and
non-accelerated scans available at baseline, 6- and 12-
months are shown in Table 1.
Quality Control (QC) of MRI Scans
First, imaging sites were instructed to immediately assess the
quality of T1 weighted scans and to re-acquire if necessary;
therefore in some cases more than one accelerated or non-
accelerated T1 weighted scan was acquired in a particular
session. QC was performed on all MRI scans at the Mayo
Clinic before being released for download. This QC procedure
entailed assessment of MRI scans for adherence to the ADNI
scanning protocol, medical abnormalities and severe artefacts
(such as metal-induced artefacts, head-coil failure etc.).
Only scans that passed this initial QC are available for
download and so all analyses in this paper were only per-
formed on the subset that passed initial QC by Mayo. At the
Dementia Research Centre (UCL) further quality assessment
of the MRI scans available to download was performed: indi-
vidual scans were assessed visually for artefacts and very poor
quality scans were excluded from further analysis (e.g. due to
severe motion artefacts); once the scans were segmented and
scan pairs registered (as detailed below), a single rater (EM),
blinded to BSI values, assessed the quality of registered scan
pairs. This assessment specifically looked at quality differ-
ences between the scans that may have affected the BSI mea-
sures. If a scan failed at this QC stage (from here on referred to
as DRC QC), it was considered as failed for all BSI measures.
The BSI measures how much the boundary of a brain re-
gion has shifted between successive scans using normalised
voxel intensities of co-registered images. Blurring due to pa-
tient motion can change the intensities of voxels at the brain
boundary and may therefore render the BSI measure unreli-
able (Preboske et al. 2006). Since subjects had more opportu-
nity to move during the longer non-accelerated scan we used a
strict quality control process (i.e. erring on the side of exclud-
ing scans) as our first aim was to investigate whether the
image acquisition, rather than differences in motion, might
influence BSI measures. If motion, geometric distortions
(due to different positioning in the scanner) or significant
quality differences between baseline and follow-up scans were
found, they were rated as unusable (for a more detailed de-
scription of the registration quality control process see
Appendix). In addition, we excluded any subjects whose
follow-up scans were performed on a different scanner from
the baseline scans.
In order to test the reproducibility of the QC rating,
the rater, blinded to diagnosis and scanner manufacturer,
re-rated a sample of 60 scan pairs. The sample
consisted scan pairs from 15 controls, 15 EMCI, 15
LMCI and 15 AD subjects. For each of the diagnostic
groups 5 scan pairs were from GE scanners, 5 from
Siemens scanners and 5 from Phillips scanners.
Quality Comparison of Accelerated and Non-accelerated
Scans
To evaluate quality we examined the proportion of scan pairs
that passed DRC QC. Patient motion is one of the major rea-
sons a registered scan pair may fail but other reasons, such as
geometric distortions due to positional differences may occur.
We hypothesised that there may be more motion artefacts in
non-accelerated scans than accelerated due to the longer time
required for the non-accelerated scan, but that other reasons
for failing QC such as geometric distortions due to positional
differences would be independent of acquisition type.
Therefore, in order to compare scan quality we excluded
both the non-accelerated and accelerated scan pair if
either were failed for reasons other than motion.
Within the remaining scan pairs, we conducted a paired
comparison of the proportion of accelerated scan pairs
that passed DRC QC and the proportion of non-
accelerated scan pairs that passed DRC QC using the
McNemar test (McNemar 1947). Where more than one
scan was acquired per session, we used the first scan to
Table 1 Subject demographics
CN EMCI LMCI AD
Baseline
Subjects, n 231 310 173 126
Age, years 73.1 (6.1) 70.8 (7.3) 72.2 (7.5) 75.1 (7.7)
MMSE score/30 29 (1) 28 (2) 28 (2) 23 (2)
Education, years 17 (3) 16 (3) 17 (2) 16 (3)
% female 54% 46% 46% 43%
% APOE ε4 carriers 31% 46% 61% 71%
Baseline to 6 months
Subjects, n 157 235 129 52
Age, years 73.6 (6.1) 71.0 (7.2) 72.0 (7.6) 75.6 (8.0)
MMSE score/30 29 (1) 28 (2) 28 (2) 23 (2)
Education, years 17 (3) 16 (3) 17 (2) 15 (3)
% female 50% 45% 48% 38%
% APOE ε4 carriers 29% 42% 57% 77%
Baseline to 12 months
Subjects, n 122 122 103 37
Age, years 74.0 (6.0) 70.7 (7.1) 71.9 (7.4) 75.9 (7.9)
MMSE score/30 29 (1) 28 (2) 28 (2) 23 (2)
Education, years 17 (3) 16 (3) 17 (2) 15 (3)
% female 52% 44% 47% 27%
% APOE ε4 carriers 27% 44% 56% 78%
Mean (sd) shown unless otherwise indicated
CN cognitively normal, EMCI early mild cognitive impairment, LCMI
late mild cognitive impairment, AD Alzheimer’s disease, MMSE mini-
mental state examination
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be acquired in this comparison (in the BSI comparisons
we used the best scan acquired).
Segmentation and Volume Measurement
Brain regions were delineated by Multi-Atlas Propagation
and Segmentation (MAPS) (Leung et al. 2011), visually
checked and manually edited if necessary (edits included
removing skull inclusions, spillages into non-brain tissue
around the temporal lobes and cutting-off the brain stem
at the most infer ior s l ice of the cerebel lum) .
Segmentat ions were performed in nat ive space.
Ventricles (including the temporal horn and excluding
the third and fourth ventricles) were segmented using a
semi-automated technique. First the scans were registered
to standard space (using a 9-dof-6 approach: 9 degrees of
freedom (dof) registration from which the rigid body
transform is extracted and applied to image). An upper
threshold of 60% of the mean brain intensity was then
applied to separate brain tissue from the cerebrospinal
fluid. Manual editing was then performed to delineate
the ventricular boundaries where required. For hippocam-
pal segmentation, each baseline scan was first registered
to standard space and the 6- and 12-month follow-up
scans were then affinely registered to their baseline.
Hippocampal regions were then automatically segmented
using the Similarity and Truth Estimation for Propagated
Segmentations (STEPS) algorithm (Cardoso et al. 2013)
and were then manually checked and edited if necessary
(e.g. editing in missing voxels around hippocampal cysts,
removing the choroid plexus where it had been included,
matching cut-offs in baseline and repeat scans). Left and
right hippocampal volumes were summed. Differences in
the numbers of scans with brain, ventricle and hippocam-
pal volumes available were due to the workflow at the
Dementia Research Centre, whereby scans are released
for segmentation in batches and all regions are manually
checked and edited where necessary. This means that not
all available scans had hippocampal regions segmented
and checked at the time of writing. We chose to include
all available scans to maximise the numbers for the
analyses.
Volume Change Measurement
For whole brain volume change, the 6- and 12-month
scans were registered to the baseline scans using affine
registration (12dof) and differential bias correction was
applied. Likewise, for measuring ventricular volume
change, the 6 and 12-month scans were registered to
the baseline scans (which were registered to standard
space prior to segmentation) using affine registration
(12dof). Local 6-dof registration was performed sepa-
rately for left and right side hippocampi after segmen-
tation using the hippocampal regions dilated by 2
voxels. Volume change between follow-up and baseline
was calculated using the robust boundary shift integral
(KN-BSI) (Leung et al. 2010) for the whole-brain, using
the fixed window BSI for the ventricles and using the
double window BSI for the hippocampi (Leung et al.
2010). Left and right hippocampal atrophy rates were
summed.
Comparison of Accelerated and Non-accelerated Volumes
and Atrophy Rates
We used paired t-tests to compare baseline mean vol-
umes between accelerated and non-accelerated scans and
compared variance between accelerated and non-
accelerated scans using Pitman’s test for equality of
variance in paired samples. All statistical tests were per-
formed in Stata 14.
To compare atrophy rates between accelerated and non-
accelerated scan pairs we used a family of linear mixed
models developed for the analysis of repeated measures of
direct change (Frost et al. 2004). We only included scans that
passed DRCQC in this analysis. These models account for the
correlation between repeated atrophy measures and permit
inclusion of all available atrophy measures in the analysis
under the assumption that missing values are missing at ran-
dom. The dependent variables in separate models were the ml
loss of brains, ventricles and hippocampi as calculated by the
BSI (see equation below). Time (years) between baseline and
follow-up scans was included as a fixed-effect. Interactions
terms between scan type and time were included to allow
atrophy rate to vary with scan type. Random effects for visit
were included to allow participants to have visit specific de-
viations from a linear trajectory, and random effect for time
allow for participant specific differences from the mean rate of
atrophy. The random effect of time was allowed to differ by
diagnostic group to allow for differing between subject het-
erogeneity in atrophy rate. The model can be written as
Eq. (1):
yijk ¼ β0 þ β1scantypeþ β2EMCIþ β3LMCIþ β4ADþ bi;C þ bi;EMCI þ bi;LMCI þ bi;AD
 
tijk − uij
þ uik þ εa;ijk þεna;ijk
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bi;C∼N 0;σ2b;C
 
; bi;EMCI∼N 0;σ2b;EMCI
 
; bi;LMCI∼N
0;σ2b;LMCI
 
; bi;AD∼N 0;σ2b;AD
 
uij∼N 0;σ2u
 
; uik∼N 0;σ2u
 
; εa;ijk∼N 0;σ2a;ε
 
; εna;ijk∼N 0;σ2na;ε
 
Where yijk is the measured change between the j-th
and k-th visit for the i-th individual, tijk is the time
interval between visits j and k, scantype is a categorical
variable representing scan type (0 if accelerated, 1 if
non-accelerated), EMCI is a categorical variable
representing EMCI status (0 if not diagnosed as
EMCI, 1 if diagnosed as EMCI) and likewise for
LMCI and AD, β0 is the mean atrophy rate in acceler-
ated scans in controls, β1 is the difference in mean
atrophy rate between accelerated and non-accelerated
scans and β2, β3,β4 are the fixed effects coefficients
corresponding to a diagnosis of EMCI, LMCI or AD,
bi terms are the random effect slope for subject i in the
relevant diagnostic group and εa,ijk and εna,ijk are the
error terms for accelerated and non-accelerated scans
respectively.
We hypothesised the residual error (εijk) may differ
between non-accelerated scans and accelerated scans, as
this represents the measurement error introduced in
making the direct BSI measurement of atrophy. It was
assumed that all other variance components, such as
between subject heterogeneity in their atrophy rates
could not be plausibly influenced by the scan type.
Therefore, in order to test for differences in variance
between accelerated and non-accelerated scans we used
the likelihood ratio test on nested models, differing only
in that one model specified with common residual var-
iance (εijk) and one model had separate residual vari-
ances by scan type (εa , ijk ; εna ,ijk).
Comparison of Subject Characteristics between Passed
and Failed Scans
We compared baseline MMSE, age and vascular burden-
white matter hyperintensity (WMH) volumes (segmented
on the FLAIR scans at UC Davis using an automated
technique) (DeCarli et al. 1999) in subjects with scan
pairs that failed QC (where one or both of the 0–6 and
0–12 month scan pairs failed DRC QC due to motion)
with those who had only passed scan pairs (either 0–6
or 0–12 months or both if available) using linear regres-
sion separately by scan type (accelerated or non-accel-
erated). For the MMSE score comparison we adjusted
for age, gender, years of education and diagnosis. For
the WMH volume comparison we adjusted for age,
baseline diagnosis and head size. Since WMH volumes
and MMSE scores are not normally distributed we used
bootstrapping (with 2000 iterations) to calculate bias-
corrected and accelerated 95% confidence intervals
(CI) for both of these analyses. For the age comparison
we adjusted for baseline diagnosis, as the AD subjects
were older than the EMCI subjects. We also compared
the proportion of subjects with cognitive impairment
(EMCI, LMCI or AD) between the groups (failed vs
non-failed scans) using logistic regression and calculated
odds ratios.
Sample Size Estimates
We estimated sample size requirements for a clinical
trial to measure a 25% reduction in whole-brain atrophy
rates in accelerated and non-accelerated scans using the
standard formula: sample size per arm = (u +
v)2 × (σ12 + σ22)/(μ1 − μ2)2 where u = 0.84 to pro-
vide 80% power and v = 1.96 to test at the 5% level; μ
and σ are the mean and SDs of rates of atrophy in the
treatment and placebo groups (assumes σ1 ≈ σ2). In
order to directly compare the sample size requirements
using accelerated and non-accelerated scans we included
all 0–6 and 0–12 month scan pairs, whether or not they
failed DRC QC.
Results
Quality Control
The majority of scans failed by Mayo were failed due
to non-adherence to the ADNI protocol, incomplete cov-
erage of the brain, metal induced artefacts or pathology.
Only one subject had scans failed by Mayo due to se-
vere motion. A total of 861 subjects had baseline accel-
erated and non-accelerated scans available to download
from LONI. Of these 840 subjects had both a baseline
accelerated and non-accelerated scan that passed DRC
first pass QC. See Fig. 1 for a detailed breakdown of
the number of subjects at each stage of the DRC QC.
Of the 573 subjects who had scans available at
6 months, scan pairs from 29 subjects were rated as
unusable due to geometrical distortions due to position-
ing differencing in the scanner being detected on either
or both of the accelerated and non-accelerated scans. A
further 138 subjects had either an accelerated or non-
accelerated scan pair rated as unusable due to motion.
Of the 384 subjects who had scans available at
12 months, geometric distortion was detected on either
the accelerated or non-accelerated scan pairs or both for
5 subjects and were therefore rated as unusable and a
further 99 subjects had either an accelerated or non-
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accelerated scan pair rated as unusable due to motion.
Examples of scan pairs that were failed due to motion
are shown in Appendix 1.
In the sample of 60 scan pairs that were re-rated for reli-
ability purposes there was 95% agreement between the initial
and repeat ratings (Cohen’s kappa coefficient: 0.74).
Fig. 1 Breakdown of no. of subjects at each stage (NA = non-accelerated scan, A = accelerated scan)
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Scan Quality Differences between Accelerated
and Non-accelerated T1 MRI Scans
At both 6- and 12- month intervals, significantly more (twice
as many) non-accelerated than accelerated scan pairs failed
quality control due to motion artefact (in one or other of the
scan pairs); at 6 months 14% of non-accelerated scan
pairs were failed due to motion vs 7% of accelerated
scan pairs (p < 0.001); at 12 months 20% of non-
accelerated scan pairs failed due to motion vs 9% of
accelerated scan pairs (p < 0.001).
Baseline Volumes
Table 2 summarises the mean baseline brain, ventricular
and hippocampal volumes (summed left and right) mea-
sured from the baseline MRI scans. There were no dif-
ferences in the mean baseline brain or hippocampal vol-
umes measured using accelerated scans as compared
with non-accelerated scans. The measured baseline ven-
tricular volume was on average 0.09 ml lower for non-
accelerated compared to accelerated scans. Although this
difference was statistically significant (p < 0.001) it was
very small at only 0.2% of the mean ventricular vol-
ume. There were no significant differences in variances
of any of the measures.
Atrophy Rates
The results of the comparison of annualised brain, ven-
tricular and hippocampal atrophy rates calculated using
the BSI from accelerated and non-accelerated MRI scan
pairs are shown in Table 3.
No significant differences in whole-brain, ventricular
or hippocampal atrophy rates were found in any of the
comparisons. Residual errors were generally slightly
higher for non-accelerated scans, although the difference
only reached statistical significance in the hippocampal
comparison in Philips scanners.
Comparison of Subject Characteristics between those
with Failed Scan Pairs Due to Motion and those
with Passed Scan Pairs
Unadjusted baseline WMH volumes, age and MMSE scores
are shown in Table 4. The results have been dichotomised by
scan quality; those whose 0–6 & 0–12 months scan pairs both
passed QC (if available) and those who had one or both of the
0–6 and 0–12 month scan pairs fail QC. The results of the
regression analyses comparing these variables between these
two subject groups are also shown.
In Accelerated Scan Pairs
Subjects who had a failed 0–6 or 0–12month accelerated scan
pair (due to motion) had a lower mean adjustedWMH volume
(adjusted for age, diagnosis and head-size) and had a higher
mean adjusted age (adjusted for diagnosis). There was no
significant association between the proportion of cognitively
impaired subjects and QC failure due to motion, nor was an
association found between baseline MMSE score and QC
scan pair failure.
In Non-accelerated Scan Pairs
A higher proportion (11% higher) of subjects who had a failed
0–6 or 0–12 month non-accelerated scan pair (due to motion)
were cognitively impaired (with a diagnosis of MCI or AD)
compared with those whose scan pairs passed QC (p = 0.01).
Subjects who had a failed 0–6 or 0–12 month non-accelerated
scan pair (due to motion) also had a lower mean adjusted
MMSE score (adjusted for age, gender, education and diag-
nosis) (p ≤ 0.05). No significant difference in WMH volumes
or age was found.
Sample Size Estimates
Mean annualised brain atrophy rates by diagnostic group are
shown in Table 5 and estimated sample sizes for subjects with
LMCI and AD are shown in Table 6. No significant
Table 2 Baseline volumes (mean (sd) unless otherwise stated)
Non-accelerated Accelerated Mean difference (non-accelerated
- accelerated) [95\%\ CI]
Limits of agreement (accelerated
_ non-accelerated)
Brain volume (ml) n = 840 1066 (106) 1066 (106) 0.3 [−0.03, 0.6], p = 0.07 -9.22 to 9.83
Ventricular volume (ml) n = 840 39.2 (22.8) 39.3 (22.8) -0.09 [−0.1, −0.06], p < 0.001 -0.81 to 0.63
Hippocampal volume
(left + right) (ml)
n = 645 5.2 (0.03) 5.2 (0.03) -0.002 [−0.004, 0.008], p = 0.5 -0.15 to 0.15
*paired t-tests were performed combining all subject categories (CN, EMCI, LMCI, AD)
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differences in sample size requirements were found when
comparing accelerated and non-accelerated scan pairs for
any of the atrophy measures.
Discussion
We have shown that using an accelerated scan protocol, which
reduces acquisition time compared with non-accelerated pro-
tocols, results in fewer scan pairs being excluded from subse-
quent analysis due to motion artefacts (which may affect the
BSI) without significantly altering the absolute rates of change
or sample sizes required for clinical trials.
The differences, adjusted for diagnosis, varied by scanner
manufacturer. Differences in atrophy rates calculated from
accelerated and non-accelerated scans from GE scanners were
higher than in Siemens and Philips scanners. Residual errors
were in general higher in non-accelerated scans, although the
difference only reached statistical significance in the hippo-
campal comparison in Philips scanners. We also found differ-
ences in the characteristics of those who failed the accelerated
and non-accelerated scan pairs: those who had failed non-
accelerated scan pairs had lower MMSEs at baseline (more
severe) and a higher proportion of them were cognitively im-
paired; whereas those whose accelerated scan pairs failed
DRC QC were older and had greater WMH volumes. The
difference in WMH volumes remained after adjustment for
age. This may be the result of scan order: accelerated scans
were always performed after non-accelerated scans and it
could be that subjects with higherWMH volumes were unable
Table 3 Comparison of whole-brain ventricular and hippocampal atrophy rates calculated from accelerated and non-accelerated scan pairs using the
boundary shift integral in subjects whose accelerated and non-accelerated scan pairs both passed QC, mean (se) shown unless otherwise indicated
No.
scan
pairs
Mean adjusted
atrophy rate*^
in accelerated
scans, ml/year
Mean adjusted
atrophy rate*^
in non-accelerated
scans, ml/year
Mean difference in
atrophy rates*
(non-accelerated -
accelerated) [95% CI]
Residual
error:
accelerated
scans
Residual
error: non-
accelerated
scans
p-value of
likelihood
ratio test
Brains
All 487 5.81 (0.88) 5.85 (0.88) 0.04
[−0.28 to 0.36], p = 0.802
5.41 (0.57) 6.66 (0.60) p = 0.153
GE 91 6.52 (1.99) 7.12 (2.01) 0.60
[−0.65 to 1.86], p = 0.347
12.71 (2.68) 19.16 (3.53) p = 0.153
Siemen-
s
289 6.44 (1.23) 6.44 (1.23) 0.00
[−0.36 to 0.36], p = 0.986
0.48 (0.90) 1.11 (0.95) p = 0.358
Philips 107 4.61 (1.99) 4.31 (1.99) -0.30
[−0.72 to 0.13], p = 0.168
2.25 (0.58) 2.91 (0.60) p = 0.506
Ventricles
All 487 1.30 (0.22) 1.30 (0.22) 0.01
[−0.02 to 0.03], p = 0.619
0.01 (0.01) 0.01 (0.01) p = 0.589
GE 91 0.86 (0.52) 0.92 (0.52) 0.06
[−0.03 to 0.15], p = 0.225
0.01 (0.03) 0.04 (0.03) p = 0.483
Siemen-
s
289 1.57 (0.27) 1.57 (0.27) 0.00
[−0.03 to 0.03], p = 0.998
0.001 (0.005) 0.01 (0.01) p = 0.450
Philips 107 0.92 (0.53) 0.91 (0.53) -0.01
[−0.07 to 0.04], p = 0.647
0.02 (0.01) 0.00 (0.01) p = 0.492
Hippocampi (sum of left and right)
All 227 0.05 (0.02) 0.04 (0.02) -0.01
[−0.02 to 0.00], p = 0.262
0.004 (0.000) 0.004 (0.0005) p = 0.795
GE 45 -0.06 (0.09) -0.08 (0.09) -0.02
[−0.05 to 0.00], p = 0.100
0.003 (0.002) 0.002 (0.002) p = 0.347
Siemen-
s
126 0.07 (0.01) 0.06 (0.01) -0.01
[−0.02 to 0.00], p = 0.125
0.001 (0.001) 0.002 (0.001) p = 0.381
Philips 56 0.03 (0.02) 0.04 (0.02) 0.01
[−0.00 to 0.03], p = 0.121
0.002 (0.000) 0.003 (0.001) p = 0.045
Significant differences (p ≤ 0.05) are shown in bold
*Difference between non-accelerated and accelerated scans for all participants whose scan pairs passed DRC QC. Results are from the model with two
separate residual errors by scan type
^Mean adjusted rates shown are for controls for illustration
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to remain still for both scans (the non-accelerated scan as well
as the accelerated scan) or it may suggest that subjects with
more extensive white matter damage are less able to remain
sufficiently motionless even at the shorter scanning times.
Regardless, disregarding data from subjects with unusable
scans due to motion changes the characteristics of the partic-
ipants included in any analysis, meaning that they may have
different characteristics from those who were originally re-
cruited to the study.
One prior study investigated the influence of changing
from a non-accelerated scanning protocol at the baseline to
an accelerated protocol at repeat on the BSI and
deformation-based morphometry atrophy measures (Leung
et al. 2015). They found that the extent to which this change
in protocol influenced atrophy measures depended on manu-
facturer, with little effect for some acquisitions and manufac-
turers. Another previous study investigated the influence of
parallel imaging acquisition on brain volumemeasurements in
Table 4 Comparison of subject characteristics (mean (sd) shown, unless otherwise stated)
Both (if available) 0–6 and 0–12
month scan pairs passed QC
One or both of the 0–6 and 0–12
month scan pairs failed QC
Adjusted difference [95% CI]
Accelerated scan pairs
WMH volume (mm3) 6.55 (8.96), n = 498 9.40 (9.71), n = 66 2.01a [0.01, 4.62], p ≤ 0.05
Age (years) 72.2 (7.4), n = 513 74.3 (6.7), n = 66 2.2b [0.4, 4.0], p = 0.02
Baseline MMSE/30 27.8 (2.4), n = 513 27.7 (2.1), n = 66 0.1c [−0.3, 0.4], p > 0.05
% Subjects cognitively impaired 73% 78% 4% [−6, 15], p = 0.45
Non-accelerated scan pairs
WMH volume (mm3) 6.85 (9.28), n = 444 7.01 (8.40), n = 120 -0.32a [−1.82, 1.49], p > 0.05
Age (years) 72.3 (7.2), n = 455 72.9 (7.6), n = 124 0.9b [−0.6, 2.3], p = 0.24
Baseline MMSE/30 27.9 (2.3), n = 455 27.3 (2.5), n = 124 -0.3c [−0.6, −0.1], p ≤ 0.05
% Subjects cognitively impaired 71% 82% 11% [19, 3], p = 0.01
Significant differences (p ≤ 0.05) are shown in bold
a Difference in mean WMH volume adjusted for age, diagnosis and headsize using linear regression analysis. CI calculated using bootstrapping
bDifference in baseline age adjusted for diagnosis using linear regression analysis
c Difference in baseline MMSE score adjusted for age, education and diagnosis. CI calculated using bootstrapping
Table 5 Atrophy rates by diagnosis in all subjects (regardless of whether scan pairs passed or failed QC)
0–6 month atrophy rates 0–12 month atrophy rates
n= Non-accelerated scans Accelerated scans n= Non-accelerated scans Accelerated scans
Annualised whole-brain atrophy rates ml/year
CN 157 7.21 (14.65) 6.74 (13.71) 122 7.18 (7.7) 7.37 (7.48)
EMCI 234 7.44 (13.89) 7.52 (14.15) 122 7.82 (8.92) 7.50 (8.35)
LMCI 129 11.48 (15.01) 11.16 (14.25) 103 10.84 (9.68) 11.01 (9.18)
AD 52 16.00 (15.97) 16.06 (15.06) 37 14.89 (8.24) 14.94 (9.20)
Annualised ventricular expansion rates ml/year
CN 157 1.31 (2.45) 1.42 (2.59) 122 1.43 (1.54) 1.41 (1.52)
EMCI 234 1.40 (2.47) 1.39 (2.51) 122 1.77 (1.81) 1.76 (1.79)
LMCI 129 2.70 (3.17) 2.70 (3.09) 103 2.94 (2.59) 2.91 (2.59)
AD 52 4.20 (4.21) 4.39 (4.17) 37 4.14 (3.01) 4.16 (2.95)
Annualised hippocampal atrophy rates (left + right) ml/year
CN 115 0.08 (0.22) 0.08 (0.22) 92 0.06 (0.11) 0.07 (0.11)
EMCI 180 0.06 (0.17) 0.07 (0.17) 85 0.09 (0.14) 0.1 (0.14)
LMCI 95 0.15 (0.23) 0.14 (0.22) 76 0.13 (0.15) 0.14 (0.14)
AD 38 0.20 (0.16) 0.21 (0.21) 25 0.18 (0.12) 0.18 (0.11)
Mean (sd) shown unless otherwise indicated
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4 healthy control subjects (Krueger et al. 2012). They
acquired 12 MPRAGE volumes in each session with a
range of acceleration factors. They then repeated the
same sequences 8 weeks later in each of the 4 subjects
and found no significant differences in BSI measures
even at high acceleration factors.
A further three previous studies investigated the influence
of using accelerated T1 acquisitions on different measures of
brain atrophy rate (Ching et al. 2015; Hua et al. 2016; Vemuri
et al. 2015). These studies all used data fromADNI. One study
(Ching et al. 2015) and it’s extension (Hua et al. 2016) found
that measures of atrophy rate derived from tensor based mor-
phometry were very similar between accelerated and non-
accelerated acquisitions. Another study (Vemuri et al. 2015),
which used a different atrophy rate measure based on symmet-
ric diffeomorphic image normalisation and tensor based mor-
phometry (TBM-Syn), did find some significant differences,
with accelerated scan pairs tending to show higher TBM-Syn
scores (or lower rates of atrophy) compared with non-
accelerated pairs. Although previous studies have compared
accelerated and non-accelerated scans for measures of atrophy
based on TBM, different measures of atrophy are based on
different properties of MRI scans and it may be that some
measures are more affected by using accelerated protocols
than others. For instance, it may be that TBM-Syn measures
are more sensitive to differences in accelerated and non-
accelerated scans (although the differences found in that study
may have also been due to the more liberal inclusion of scans
with motion than in this study). This is the first study to date to
examine the impact of using accelerated scans in place of non-
accelerated scans at both baseline and follow-up on the BSI –
a measure used as a secondary outcome in clinical trials of
treatments in AD. In addition, we investigated the influence of
scanner manufacturer on atrophy rate outcomes as well as the
demographics and vascular burden of those who had good
quality vs. poor quality serial images, which adds to the
existing literature.
There are some limitations to this study. First, subjects
always had the non-accelerated scan prior to the accelerated
scan. It could be that the finding of more motion artefacts in
the non-accelerated scans was due to the ordering of the scans
rather than the longer scan time. Secondly, the motion arte-
facts were visually rated and the rater was not blinded to the
type of scan performed, which may have introduced some
bias. We performed considered QC in order to be able to test
the specific hypotheses of interest. However, it may be that
had another rater performed this QC, different results may
have been obtained. We did not assess rescans as part of the
quality comparison as we wished to assess how quality was
affected in the first scan of each type obtained. It may be that
assessing rescans in place of original scans may have changed
the results presented. Thirdly, given the importance of head
coils on the quality of scans, it would be interesting to inves-
tigate the influence of head coil type on the differences be-
tween accelerated and non-accelerated scans. Unfortunately
details of head coils usedwere not available for a large number
of the ADNI subjects, so we were unable to perform this
analysis in this study. Further, although our results indicate
that atrophy rates measured using the BSI in accelerated scans
are not markedly different from those measured in non-
accelerated scans, it may be that different techniques for mea-
suring brain atrophy rates are more susceptible to the changes
in scan characteristics introduced by parallel imaging tech-
niques. Notably, the differences in hippocampal atrophy rates
between accelerated and non-accelerated scans were relatively
higher than the differences in whole-brain and ventricular
Table 6 Sample size estimates for a 25% reduction in atrophy rate with bootstrap 95% CIs and 80% power
non-accelerated scans,
n [95% CI]
Accelerated scans,
n [95% CI]
Difference (non-accelerated -
accelerated), n [95% CI]
Baseline to 6 months
LMCI Brains 420 [257, 858] 414 [258, 759] 6 [−100, 146]
LMCI Ventricles 349 [241, 692] 334 [226, 633] 15 [−38, 50]
LMCI Hippocampi 673 [342, 1851] 612 [340, 1707] 61 [−226, 763]
AD Brains 252 [146, 606] 223 [127, 529] 29 [−65, 248]
AD Ventricles 254 [160, 466] 228 [145, 427] 26 [−3, 75]
AD Hippocampi 145 [89, 270] 236 [136, 576] -91 [−153, 19]
Baseline to 12 months
LMCI Brains 204 [139, 371] 177 [127, 277] 27 [−14, 76]
LMCI Ventricles 202 [148, 320] 205 [149, 329] -3 [−16, 10]
LMCI Hippocampi 361 [221, 853] 234 [160, 415] 127 [−16, 435]
AD Brains 77 [53, 126] 96 [56, 203] -19 [−47, 23]
AD Ventricles 134 [89, 244] 127 [85, 232] 7 [−1, 20]
AD Hippocampi 110 [58, 328] 93 [40, 621] 17 [−64, 172]
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atrophy rates (~30% difference in hippocampal atrophy rates
between accelerated and non-accelerated scans on Philips and
GE scanners and ~15% difference on Siemens scanners) al-
though the differences were not statistically significant. The
SNR ratios in accelerated scans are highest near the head coils,
on the surface of the brain and get progressively worse, as the
distance from the coils increases (Krueger et al. 2012). The
hippocampal BSI may therefore be more sensitive to the dif-
ferences in accelerated and non-accelerated scans due to their
location deep in the brain. It may be that with longer time
intervals, these differences become more apparent and further
studies would be required to investigate this.
In summary, the shorter scan time of accelerated scans may
reduce the proportion of first-acquisition scans affected by
motion artefacts. Therefore it may be advantageous to use
accelerated T1 MRI scans rather than non-accelerated scans
for assessing brain volumes and atrophy rates (BSI) in clinical
trials. Importantly, the use of accelerated T1 structural MRI
scans in place of non-accelerated scans does not appear to
have an impact on whole-brain, ventricular and hippocampal
volume and atrophy rate (BSI) measures. Finally, differences
in subject characteristics were observed in those subjects
whose scan pairs passed DRC QC from those whose scan
pairs failed DRC QC due to motion in both accelerated and
non-accelerated scans. Disregarding data from subjects who
are unable to keep sufficiently still during an MRI scan to
produce quality data ultimately biases the characteristics of
the subject group in some way, possibly excluding those sub-
jects who are more severe or have a more vascular form of the
disease. However, the use of accelerated T1 volumetric scans
rather than non-accelerated T1 volumetric scans may mean
that higher quality longitudinal images can be obtained on a
larger proportion of the original study population.
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